Polycomb inhibitors belong to a specific chemical class of compounds that have been studied and designed to selectively target and inhibit the activity of Polycomb group (PcG) proteins. The PcG proteins are involved in epigenetic regulation and play a crucial role in maintaining gene silencing and controlling cell fate during development. Inhibition of Polycomb proteins aims to disrupt their function in epigenetic mechanisms and potentially modulate gene expression and cell differentiation processes. The chemical structures of Polycomb inhibitors can vary, including small-molecule compounds that specifically interact with Polycomb proteins and interfere with their interactions with chromatin or other regulatory molecules.
Researchers have explored various strategies to target Polycomb proteins and attenuate their effects on gene silencing and cellular identity. The study of Polycomb inhibitors provides valuable insights into the complex regulatory mechanisms governing epigenetic processes and cellular development. Continued research in this chemical class holds promise for advancing our understanding of the role of Polycomb proteins in cellular physiology
.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
This is a specific inhibitor of the PRC2 subunit, enhancer of zeste homolog 2 (EZH2), and has been studied for its potential therapeutic effects in cancer. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
Another small-molecule compound that inhibits EZH2 and has been explored as a potential epigenetic therapy in cancer. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is a selective inhibitor of EZH2 that has shown promise in research studies for cancer research. | ||||||
Epz004777 | 1338466-77-5 | sc-507560 | 100 mg | $575.00 | ||
This is a small-molecule inhibitor that targets the PRC2 and has been studied for its potential to reverse gene silencing in cancer cells. | ||||||